Yaron Pereg, KAHR CEO

An Is­raeli biotech is look­ing to make its name in the jam-packed CD47 space. Is bi­func­tion­al­i­ty the an­swer?

Jerusalem’s KAHR Med­ical had been work­ing on fu­sion pro­teins for au­toim­mune dis­or­ders for about 10 years, be­fore “is­sues in de­vel­op­ment” spurred then-new CEO Yaron Pereg to change gears in 2017.

“We had done our gap analy­sis and thought, ‘This is a very cool tech­nol­o­gy and very in­ter­est­ing plat­form, why won’t we start from scratch, do things dif­fer­ent and al­so se­lect more nov­el tar­gets?’” he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.